Lingyi Biotech registers third GBA1 gene therapy trial for Parkinson's, joins crowded field
The Early Phase 1 China study enters a target-indication pairing with a 100% termination rate to date, testing safety before any efficacy signal in 18 patients.
Executive Summary
- Lingyi Biotech Co., Ltd. registered an Early Phase 1 trial of LY-N001, an intracerebral gene therapy for GBA1-mutation Parkinson's disease in 18 patients, becoming the third company to test a direct GBA1-targeted gene therapy in this indication NCT07685444A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Injection of LY-N001 Injection for the Treatment of Moderate to Advanced Parkinson's Disease With GBA1 MutationsNCT07685444.
- The primary endpoints measure adverse event incidence and dose-limiting toxicity, not motor or cognitive improvement, so this trial cannot establish efficacy even if it enrolls and completes on schedule.
- The GBA1 x Parkinson's disease pairing has a 100% termination rate among prior trials, with zero completions recorded to date, setting a demanding bar before LY-N001 generates any usable signal.
- Two other sponsors, Prevail Therapeutics and Shanghai Vitalgen BioPharma, already run direct GBA1 gene therapy programs in the same indication, meaning LY-N001 enters an established competitive lane rather than opening new ground.
- AppliedXL has no probability model on record for this catalyst, so the trial's odds of a positive safety or efficacy signal remain unassessed by the model at this stage.
The filing
Lingyi Biotech Co., Ltd. added NCT07685444 to ClinicalTrials.gov on July 6, 2026, registering an Early Phase 1 study of a single intracerebral injection of LY-N001 in patients with moderate to advanced Parkinson's disease carrying pathogenic GBA1 variants NCT07685444+1A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Injection of LY-N001 Injection for the Treatment of Moderate to Advanced Parkinson's Disease With GBA1 MutationsNCT07685444Press ReleaseJul 6, 2026. The trial plans to enroll 18 patients aged 30 to 70 at a single site in China, with a start date of July 7, 2026 and a primary completion date of July 7, 2028. The study is not yet recruiting NCT07685444A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Injection of LY-N001 Injection for the Treatment of Moderate to Advanced Parkinson's Disease With GBA1 MutationsNCT07685444.
What the trial measures
The registered primary outcome is the incidence of treatment-emergent and serious adverse events within 52 weeks of administration, alongside dose-limiting toxicity assessed within 28 days. All events will be graded per CTCAE Version 6.0. Sixteen secondary measures track motor function via MDS-UPDRS Part III, cognitive scales, quality of life, and biomarkers including cerebrospinal fluid glucocerebrosidase activity, but these are exploratory, not primary. A safety-primary, open-label, single-arm design in 18 patients is built to characterize tolerability, not to demonstrate a treatment effect.
The competitive field
LY-N001 is not the first gene therapy aimed at GBA1-mutation Parkinson's disease. Prevail Therapeutics' LY3884961 (PR001) has run a Phase 1/2a trial in the same population since 2020, now active but not recruiting, with a primary completion date of December 31, 2030. Shanghai Vitalgen BioPharma's VGN-R08b targets the same population in a Phase 1/2 trial not yet recruiting, with completion targeted for September 1, 2027. Both qualify as direct comparators on target, modality, and indication.
The difficulty bar
The GBA1 x Parkinson's disease pairing carries a landscape score of 51, rated challenging, with 4 trials across 4 sponsors reaching a maximum phase of Phase 2. Of prior trials in this exact pairing, zero completed and one terminated, a 100% termination rate with one distinct company having failed. That history does not predict LY-N001's outcome, but it sets the bar this program must clear where prior attempts have not.
What stays open
The trial carries no FDA designation of any kind and no US site, and LY-N001 has no prior approval history under any indication. Protocol stability is rated 'Stable' with zero recorded change events, though the trial has only just been registered and has not begun recruiting. No results are posted on ClinicalTrials.gov, and no historical outcomes exist yet for LY-N001 itself.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.